According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “
NTUS traded down $0.14 during trading hours on Friday, reaching $31.74. 164,400 shares of the stock traded hands, compared to its average volume of 241,076. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 22.35 and a beta of 0.63. Natus Medical has a fifty-two week low of $22.25 and a fifty-two week high of $37.90. The company has a current ratio of 1.93, a quick ratio of 1.36 and a debt-to-equity ratio of 0.15.
Natus Medical Company Profile
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Featured Article: Can systematic risk be avoided?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.